SAN JOSE, Calif., Jan. 13, 2021 /PRNewswire/ -- Anixa
Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer and infectious diseases,
announced today that Dr. Amit Kumar,
Anixa's Chief Executive Officer, will present at B. Riley's
Inaugural Oncology Investor Conference to be held January 20-21, 2021.
Dr. Kumar will participate in a fireside chat presentation to
discuss Anixa's recent accomplishments and anticipated milestones.
Company management will also be available to participate in
online one-on-one meetings with investors who are registered to
attend the conference.
Anixa's presentation will be live webcast at 10:30 a.m. PST on January
21, 2021. The presentation will be open to registered
conference attendees, institutional investors and investor
relations professionals, who may register to view the live webcast
at
https://b-riley-oncology-investor-conference.events.issuerdirect.com/signup.
After completion of the event, a replay of the presentation
will be publicly available on the Anixa website at
https://ir.anixa.com/events.
About Anixa Biosciences, Inc.
Anixa is a
publicly-traded biotechnology company developing a number of
programs addressing cancer and infectious disease. Anixa's
therapeutics portfolio includes a cancer immunotherapy program
which uses a novel type of CAR-T, known as chimeric endocrine
receptor T-cell (CER-T) technology, and a Covid-19 therapeutics
program focused on inhibiting certain viral protein function.
The company's vaccine portfolio includes a vaccine to prevent
breast cancer, and specifically triple negative breast cancer
(TNBC), the most deadly form of the disease, and a vaccine to
prevent ovarian cancer. These vaccine technologies focus on
immunizing against specific proteins that have been found to be
expressed in certain forms of cancer. Anixa continually
examines emerging technologies in complementary fields for further
development and commercialization. Additional information is
available at www.anixa.com.
Forward-Looking Statements: Statements that
are not historical fact may be considered forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are not
statements of historical facts, but rather reflect Anixa's current
expectations concerning future events and results. We
generally use the words "believes," "expects," "intends," "plans,"
"anticipates," "likely," "will" and similar expressions to identify
forward-looking statements. Such forward-looking statements,
including those concerning our expectations, involve risks,
uncertainties and other factors, some of which are beyond our
control, which may cause our actual results, performance or
achievements, or industry results, to be materially different from
any future results, performance, or achievements expressed or
implied by such forward-looking statements. These risks,
uncertainties and factors include, but are not limited to, those
factors set forth in "Item 1A - Risk Factors" and other sections of
our most recent Annual Report on Form 10-K as well as in our
Quarterly Reports on Form 10-Q and Current Reports on Form
8-K. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Investor contact:
Mike Catelani
mcatelani@anixa.com
408-708-9808
Media contact:
Sherry Ash
anixapress@gmail.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-to-present-at-the-b-riley-oncology-investor-conference-301207339.html
SOURCE Anixa Biosciences, Inc.